Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previously treated with a rituximab based regimen

Trial Profile

Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previously treated with a rituximab based regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Ofatumumab (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 11 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top